Genes, Vol. 12, Pages 1631: Identification of Novel Endogenous Controls for qPCR Normalization in SK-BR-3 Breast Cancer Cell Line

Genes, Vol. 12, Pages 1631: Identification of Novel Endogenous Controls for qPCR Normalization in SK-BR-3 Breast Cancer Cell Line Genes doi: 10.3390/genes12101631 Authors: Nityanand Jain Ingrida Mitre Dina Nitisa Valdis Pirsko Inese Cakstina-Dzerve Normalization of gene expression using internal controls or reference genes (RGs) has been the method of choice for standardizing the technical variations in reverse transcription quantitative polymerase chain reactions (RT-qPCR). Conventionally, ACTB and GAPDH have been used as reference genes despite evidence from literature discouraging their use. Hence, in the present study we identified and investigated novel reference genes in SK-BR-3, an HER2-enriched breast cancer cell line. Transcriptomic data of 82 HER2-E breast cancer samples from TCGA database were analyzed to identify twelve novel genes with stable expression. Additionally, thirteen RGs from the literature were analyzed. The expression variations of the candidate genes were studied over five successive passages (p) in two parallel cultures S1 and S2 and in acute and chronic hypoxia using various algorithms. Finally, the most stable RGs were selected and validated for normalization of the expression of three genes of interest (GOIs) in normoxia and hypoxia. Our results indicate that HSP90AB1, DAD1, PFN1 and PUM1 can be used in any combination of three (triplets) for optimizing intra- and inter-assay gene expression differences in the SK-BR-3 cell line. A...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research

Related Links:

CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: KN026, a HER2 bispecific antibody, was well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab doublet even in the more heavily pretreated patients. Co-amplification of HER2/CDK12 may define patients who benefit more from KN026.PMID:34844975 | DOI:10.1158/1078-0432.CCR-21-2827
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Clin Breast Cancer. 2021 Oct 25:S1526-8209(21)00301-3. doi: 10.1016/j.clbc.2021.10.007. Online ahead of print.ABSTRACTEndocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines curre...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: KN026, a HER2 bispecific antibody, was well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab doublet even in the more heavily pretreated patients. Co-amplification of HER2/CDK12 may define patients who benefit more from KN026.PMID:34844975 | DOI:10.1158/1078-0432.CCR-21-2827
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
J Chemother. 2021 Nov 30:1-8. doi: 10.1080/1120009X.2021.2009722. Online ahead of print.ABSTRACTThe choice of the anti-HER2 agent depends on country-specific availability, the specific, previously administered anti-HER2 therapy and the relapse-free interval, although there is not much published data on the use of lapatinib after progression on pertuzumab and/or T-DM1. The aim of this research is to determine efficacy of lapatinib in this setting. This research included 111 patients with metastatic HER2 positive breast cancer who received lapatinib with capecitabine at The Oncology Institute of Vojvodina. Lapatinib was give...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: KN026, a HER2 bispecific antibody, was well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab doublet even in the more heavily pretreated patients. Co-amplification of HER2/CDK12 may define patients who benefit more from KN026.PMID:34844975 | DOI:10.1158/1078-0432.CCR-21-2827
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Clin Breast Cancer. 2021 Oct 25:S1526-8209(21)00301-3. doi: 10.1016/j.clbc.2021.10.007. Online ahead of print.ABSTRACTEndocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines curre...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Contributors : Tong Liu ; Cheng Liu ; Jing Zhang ; Xiaofan Wei ; Hongquan ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe diverse cell types in the breast cancer microenvironment regulate tumor cell growth, metastasis, and response to therapy. However, little is known about the microenvironment of lymph node metastasis (LNM). Using single-cell transcriptome analysis together with T-cell receptor (TCR) sequencing, we generated single-cell maps of breast cancers and paired LNM in 8 patients. The T cells in LNM were relatively inactive, with weaker expansion and transition abili...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | HER2 | Study